A molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib

Trial Identifier: D5161C00003
Sponsor: AstraZeneca
Collaborator:
PAREXEL
NCTID:: NCT03239340
Start Date: May 2018
Primary Completion Date: September 2023
Study Completion Date: September 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
Italian Translation
Korean Translation
Malay Translation
Tamil (Malaysia) Translation
Simplified Chinese (Malaysia) Translation

Trial Locations

Country Location
ES A Coru�a, ES, 15006
ES Barcelona, ES, 08035
ES Las Palmas de Gran Canaria, ES, 35016
ES Madrid, ES, 28046
ES Sevilla, ES, 41009
IT Brescia, IT, 25100
IT MELDOLA, IT, 47014
IT Monza, IT, 20900
IT Parma, IT, 43126
IT ROMA, IT, 00152
IT Terni, IT, 05100
KR Busan, KR, 47392
KR Cheongiu, KR, 28644
KR Seongnam, KR, 13620
KR Seoul, KR, 05505
KR Seoul, KR, 135-710
KR Seoul, KR, 06591
KR Seoul, KR, 03722
MY Johor Bahru, MY, 81100
MY Kuantan, MY, 25100
MY Kuching, MY, 93586
MY Lembah Pantai, MY, 59100
MY Pulau Pinang, MY, 10450
US, GA Athens, GA, US, 30607
US, GA Atlanta, GA, US, 30307
US, MA Boston, MA, US, 02215